[.
]
Content:
Lotrel 2.5/10:
Calcium channel blocking agent: Amlodipine, 2.5 mg.
ACE inhibitor: Benazepril hydrochloride, 10 mg. Lotrel 5/10 and Lotrel 5/20 contain 5 mg of amlodipine and either 10 or 20 mg of benazepril hydrochloride.
Action/Kinetics:
The incidence of edema is significantly reduced with this combination product.
Peak plasma levels, benazepril: 0.5-2 hr (1.5-4 hr for benazeprilat, the active metabolite).
Peak plasma levels, amlodipine: 6-12 hr.
Elimination t
1/2, benazeprilat: 10-11 hr;
elimination t
1/2, amlodipine: 2 days.
Uses:
Treatment of hypertension. Therapy with this combination is suggested when the client either has failed to achieve the desired antihypertensive effect with either drug alone or has demonstrated inability to achieve an adequate antihypertensive effect with amlodipine without developing edema.
Contraindications:
Initial treatment of hypertension. Hypersensitivity to amlodipine or benazepril. Lactation.
Special Concerns:
Discontinue ACE inhibitors as soon as pregnancy is determined. The addition of benazepril to amlodipine should not be expected to provide additional antihypertensive effects in African-Americans, although there will be less edema. Use with caution in those with severe renal disease, in CHF, and in severe hepatic impairment. Safety and efficacy have not been determined in children.
Side Effects:
See individual drugs. Side effects include angioedema, cough, headache, and edema.
How Supplied:
See Content
Dosage
?Capsules
Hypertension.
One 2.5/10 mg, 5/10 mg, or 5/20 mg capsule once daily. In those with severe renal impairment, the recommended initial dose of benazepril is 5 mg (Lotrel is not recommended in these clients). In small, elderly, frail, or hepatically impaired clients, the recommended initial dose of amlodipine (either as monotherapy or in combination) is 2.5 mg.
